arrow
Return

Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

delete2022-08-30
delete17
delete
OA
AI
P
Park, Wungki
C
Catherine O’Connor
B
Bandlamudi, Chaitanya
D
Daniella Forman
C
Chou, Joanne F.
S
Shigeaki Umeda
M
Marsha Reyngold
V
Varghese, Anna M.
K
Keane, Fergus
F
Fiyinfolu Balogun
Y
Yu, Kenneth H.
K
Kelsen, David P.
C
Crane, Christopher
C
Capanu, Marinela
I
Iacobuzio-Donahue, Christine
O
O'Reilly, Eileen M. *
DOI:10.1158/1078-0432.CCR-22-1483delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Purpose: Characterizing germline and somatic ATM variants (gATMm, sATMm) zygosity and their contribution to homologous recombination deficiency (HRD) is important for therapeutic strat-egy in pancreatic ductal adenocarcinoma (PDAC).Experimental Design: Clinico-genomic data for patients with PDAC and other cancers with ATM variants were abstracted. Genomic instability scores (GIS) were derived from ATM-mutant cancers and overall survival (OS) was evaluated. Results: Forty-six patients had PDAC and pathogenic ATM variants including 24 (52%) stage III/IV: gATMm (N = 24), and sATMm (N = 22). Twenty-seven (59%) had biallelic, 15 (33%) monoallelic, and 4 indeterminate (8%) variants. Median OS for advanced-stage cohort at diagnosis (N = 24) was 19.7 months [95% confidence interval (CI): 12.3-not reached(NR)], 27.1 months (95% CI: 22.7-NR) for gATMm (n = 11), and 12.3 months for sATMm (n = 13; 95% CI: 11.9-NR; P = 0.025). GIS was computed for 33 patients with PDAC and compared with other ATM-mutant cancers enriched for HRD. The median was lower (median, 11; range, 2-29) relative to breast (18, 3-55) or ovarian (25, 3-56) ATM-mutant cancers (P < 0.001 and P = 0.003, respectively). Interestingly, biallelic pathogenic ATM var-iants were mutually exclusive with TP53. Other canonical driver gene (KRAS, CDKN2A, SMAD4) variants were less frequent in ATM-mutant PDAC.Conclusions: ATM variants in PDAC represent a distinct bio-logic group and appear to have favorable OS. Nonetheless, path-ogenic ATM variants do not confer an HRD signature in PDAC and ATM should be considered as a non-core HR gene in this disease.
Keywords:
COLLOID CARCINOMA
SURVIVAL
MUTATIONS
ADENOCARCINOMA
BREAST
MULTICENTER
DEFICIENCY
LANDSCAPE
THERAPIES

Journal

Clinical Cancer Research cover
Clinical Cancer Research
IF:
10.2
Papers:
1.8W
Citations:
9.3W

Organization

M
Memorial Sloan Kettering Cancer Center
Scholars:
3.4W
Papers: 2.4W
Citations: 4.6W
C
Cornell University
Scholars:
6.3W
Papers: 5.4W
Citations: 10.9W